Evaluating Cordyceps militaris capsules on post-bronchodilator FEV1 decline in patients with COPD: a study protocol for double-blind, randomized, placebo-controlled trial
Lei Wu
BackgroundChronic Obstructive Pulmonary Disease (COPD) is characterized by a progressive deterioration of lung function, which occurs at its fastest rate in the early stages (GOLD I-II). Preliminary clinical investigation has suggested that Cordyceps militaris capsules can improve post-bronchodilator forced expiratory volume in 1 s (FEV1) in mild-to-moderate COPD. However, previous studies were limited by the absence of placebo control. Therefore, this trial is designed to evaluate the efficacy